At Selecta Biosciences, our vision is to profoundly impact the lives of patients by developing first-in-class antigen-specific tolerogenic therapies using our proprietary platform of Synthetic Vaccine Particles (SVP™). Our products are capable of inducing antigen-specific immune tolerance and also have the capability of activating robust immune responses both for prophylactic and therapeutic applications. The diversity of our platform enables us to address a wide range of diseases including rare diseases, autoimmune diseases, allergies, cancer, infectious diseases, and respiratory.
I am thrilled to be part of our talented and dedicated team both in Boston and Moscow. I am proud of the results we have achieved – and we will continue to make progress toward our strategic vision. We recognize and value the importance of our team members and we seek to recruit those who share our passion and are inspired by the potential of our technology to make a difference for patients. We invite you to learn more about Selecta, our people, our technology, and the many possibilities for partnerships and collaborations.
Werner Cautreels, Ph.D.
President and CEO
Selecta Biosciences, Inc.